HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bromhexine

HCID 2442
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
3572-43-8
Standard SMILES
CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
InChIKey
OJGDCBLYJGHCIH-UHFFFAOYSA-N
Molecular formula
C14H20Br2N2
Average molar mass
376.13 g/mol
Monoisotopic mass
373.99932

Overview

Bromhexine is a substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum). It has a role as a mucolytic. It is an organobromine compound, a substituted aniline and a tertiary amino compound. It is a conjugate base of a bromhexine(1+).

Names & identifiers

Preferred name
Bromhexine
IUPAC
2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline
English name
Bromohexine
Molecular formula
C14H20Br2N2
Molecular weight
376.13

Names & synonyms

bromhexine3572-43-8Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-BromhexinaBromhexinumFluibron2,4-dibromo-6-[[cyclohexyl(methyl)amino]methyl]aniline2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)anilineQ1J152VB1PCHEBI:770322,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}anilineDTXSID6022686
Show more names
BroMhexine IMpurity EBromexineAuxitNa 274Aids001646Aids-001646BromohexineAKOS B015997AURORA KA-7546
NA274N-cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine3,5-dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamineBromexinaDurElixbromhexin von ctDur ElixBC, Bromhexin

Database identifiers

CAS
3572-43-8
PubChem CID
2442
DTXSID
DTXSID6022686
ChEMBL
CHEMBL253376
ChEBI
CHEBI:77032
UNII
Q1J152VB1P
EC Number
222-684-1
Nikkaji
J8.165E

Properties

Computed structural properties

XLogP
4.3
Topological polar surface area
29.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
3
Heavy atoms
18
Formal charge
0
Complexity
256

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Solubility<1 mg/mL
Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Expectorants

Pharmaceuticals

Melting Point232-235
Dissociation Constants8.69
Collision Cross Section167.85 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
238 ℃ · 238℃
Boiling point
413.8 · 413.8±40.0 °C(Predicted)
Density
1.57 · 1.57
storage temp.
2 · 2-8°C(protect from light)
solubility
75 mg/mL · DMSO: 75 mg/mL (199.40 mM);Ethanol: 75 mg/mL (199.40 mM)
pka
8.34 · 8.34±0.20(Predicted)
Water Solubility
Water: Insoluble
InChI
InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
InChIKey
OJGDCBLYJGHCIH-UHFFFAOYSA-N
SMILES
C1(CN(C2CCCCC2)C)=CC(Br)=CC(Br)=C1N
FDA UNII
1 J152VB1P · Q1J152VB1P
ATC code
5 CB02 · R05CB02
Comptox DTXSID
6022686 · DTXSID6022686
Signal word
Warning
Hazard statements
410 · H410-H400
Precautionary statements
273 · P273-P391-P501-P273-P391-P501
HS Code
2921590090 · 2921590090
Toxicity
50 orally · Approx LD50 orally in rabbits: >10 g/kg (Boyd, Sheppard)
REACH Registrations
Active

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H400 (100%): Very toxic to aquatic life [Warning Hazardous to the aquatic environment, acute hazard]

P273, P391, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 3 items

Chemical: Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-

REACH registered substance: Bromhexine (EC: 222-684-1)

Bromhexine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Other Safety InformationIMAP assessments - Benzenemethanamine, 2-amino-3,5-dibromo-N-cyclohexyl-N-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAquatic Acute 1 (100%)

Toxicology

Drug Induced Liver Injury · 4 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Bromhexine

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

hs_code
2921590090
Toxicity
Approx LD50 orally in rabbits: >10 g/kg (Boyd, Sheppard)
Signal word
Warning
Hazard statements
H410-H400
REACH Registrations
Active
Precautionary statements
P273-P391-P501-P273-P391-P501

Chemistry & industry

Pharmacology

ATC Code · 3 items

R05CB02

R - Respiratory system

QR - Respiratory system

Protein BindingBromhexine is approximately 95% bound to plasma proteins.
PharmacodynamicsBromhexine thins airway secretions, improving breathing and discomfort associated with thick mucus in airways associated with a variety of respiratory conditions.
Mechanism of Action · 1 item

Inflammation of the airways, increased mucus secretion, and altered mucociliary clearance are the hallmarks of various diseases of the respiratory tract. Mucus clearance is necessary for lung health; bromhexine aids in mucus clearance by reducing the viscosity of mucus and activating the ciliary epithelium, allowing secretions to be expelled from the respiratory tract. Recent have studies have demonstrated that bromhexine inhibits the transmembrane serine protease 2 receptor (TMPRSS2) in humans. Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19. In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.

Biological Half-LifeFollowing single oral doses ranging from 8 and 32 mg, the terminal half-life of bromhexine has been measured between 6.6 and 31.4 hours.
Metabolism/Metabolites · 1 item

Bromhexine is almost completely metabolized to a variety of hydroxylated metabolites in addition to dibromanthranilic acid. Ambroxol is a known metabolite of bromhexine. In one study of human plasma, (E)-4-hydroxydemethylbromhexine (E-4-HDMB) and (E)-3-hydroxydemethylbromhexine (E-3-HDMB) were quantified as major metabolites of ambroxol, and (Z)-4-hydroxydemethylbromhexine and (Z)-3-hydroxydemethylbromhexine were quantified as minor metabolites.

MeSH Pharmacological ClassificationAgents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
Absorption, Distribution and Excretion · 4 items

After oral administration, bromhexine demonstrates linear pharmacokinetics when given in doses of 8-32 mg. Bromhexine is readily absorbed in the gastrointestinal tract at a rapid rate. This drug undergoes extensive first-pass effect in the range of 75-80%. The bioavailability is therefore reduced to approximately 22-27%.

After a dose of bromhexine was administered during a pharmacokinetic study, approximately 97% of the radiolabeled dose was detected in the urine; under 1% was detected as the parent drug.

After intravenous administration in a pharmacokinetic study, bromhexine was found to be widely distributed. Bromhexine is known to cross the blood-brain barrier; small concentrations may cross the placenta. The average volume of distribution of bromhexine was 1209 ± 206 L (19 L/kg). Lung tissue concentrations of bromhexine two hours after a dose were 1.5 to 3.2 times higher in bronchial tissues than plasma concentrations. Pulmonary parynchema concentrations were 3.4 to 5.9 times higher when compared to plasma concentrations.

The clearance of bromhexine ranges from 843-1073 mL/min, within the range of the hepatic circulation.

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >250
Use ClassificationPharmaceuticals

Applications

UsesExpectorant; mucolytic.

Upstream & downstream products

Upstream raw materials

2-Nitrobenzyl bromideHYDRAZINEN-Methylcyclohexylamine
Additional notes · 1 item

DefinitionChEBI: A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive ough (i.e. a cough characterised by the production of sputum).

Related reactions

1 records
New reaction record
HRID 1506608 reaction equation
HRID 1506608As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes